Awakn Life Sciences Corp.: Awakn Life Sciences Announces the Findings from the Phase II A/B Study Are to Be Published in the American Journal of Psychiatry
World's First Controlled Study to Investigate Ketamine-Assisted Psychotherapy Toronto, Ontario--(Newsfile Corp. - November 4, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn')
Source: finanznachrichten.de